Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.